Cargando…

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients

Liquid biopsy is a tool to unveil resistance mechanisms in NSCLC. We studied changes in gene expression in CTC-enriched fractions of EGFR-mutant NSCLC patients under osimertinib. Peripheral blood from 30 NSCLC patients before, after 1 cycle of osimertinib and at progression of disease (PD) was analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ntzifa, Aliki, Strati, Areti, Kallergi, Galatea, Kotsakis, Athanasios, Georgoulias, Vassilis, Lianidou, Evi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840727/ https://www.ncbi.nlm.nih.gov/pubmed/33504904 http://dx.doi.org/10.1038/s41598-021-82068-9

Ejemplares similares

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Pantazaka, Evangelia, et al.
Publicado: (2022)

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
por: Ntzifa, Aliki, et al.
Publicado: (2021)

DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment
por: Ntzifa, Aliki, et al.
Publicado: (2021)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2009)

Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer
por: Stergiopoulou, Dimitra, et al.
Publicado: (2023)

Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact
por: Vardas, Vasileios, et al.
Publicado: (2023)

Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients
por: Strati, Areti, et al.
Publicado: (2019)

CD8(+) PD-1(+) T-cells and PD-L1(+) circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
por: Kotsakis, Athanasios, et al.
Publicado: (2019)

Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
por: Chimonidou, Maria, et al.
Publicado: (2017)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer
por: Strati, Areti, et al.
Publicado: (2021)

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
por: Strati, Areti, et al.
Publicado: (2023)

Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients
por: Katsarou, Spyridoula D., et al.
Publicado: (2022)

Functional Analysis of Viable Circulating Tumor Cells from Triple-Negative Breast Cancer Patients Using TetherChip Technology
por: Vardas, Vasileios, et al.
Publicado: (2023)

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR
por: Strati, Areti, et al.
Publicado: (2011)

PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs
por: Sklias, Thodoris, et al.
Publicado: (2022)

Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting
por: Strati, Areti, et al.
Publicado: (2023)

Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer
por: Markou, Athina, et al.
Publicado: (2021)

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2008)

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2011)

Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients
por: Agelaki, Sofia, et al.
Publicado: (2016)

Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer
por: Strati, Areti, et al.
Publicado: (2013)

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2015)

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study
por: Koinis, Filippos, et al.
Publicado: (2023)

Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer
por: Zavridou, Martha, et al.
Publicado: (2021)

PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients
por: Markou, Athina, et al.
Publicado: (2020)

Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy
por: Spiliotaki, Maria, et al.
Publicado: (2014)

KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer
por: Mastoraki, Sofia, et al.
Publicado: (2020)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
por: Papadaki, Maria A, et al.
Publicado: (2014)

Expression of insulin‐like growth factor‐1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes
por: Spiliotaki, Maria, et al.
Publicado: (2017)

PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
por: Tzanikou, Eleni, et al.
Publicado: (2019)

PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
por: Racherla, Kavya Sri, et al.
Publicado: (2023)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Papadaki, Maria A., et al.
Publicado: (2021)

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse
por: Saloustros, Emmanouil, et al.
Publicado: (2011)

HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study
por: Economopoulou, Panagiota, et al.
Publicado: (2019)

Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer
por: Buszka, Karolina, et al.
Publicado: (2022)

Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma
por: Zavridou, Martha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0vtnk51lle8cp178mj62ki4p9n